CN203169191U - Vacuum blood collection tube for diabetes active peptide blood sample detection - Google Patents
Vacuum blood collection tube for diabetes active peptide blood sample detection Download PDFInfo
- Publication number
- CN203169191U CN203169191U CN 201220533564 CN201220533564U CN203169191U CN 203169191 U CN203169191 U CN 203169191U CN 201220533564 CN201220533564 CN 201220533564 CN 201220533564 U CN201220533564 U CN 201220533564U CN 203169191 U CN203169191 U CN 203169191U
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- inhibitors
- coagulants
- tube
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 31
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 27
- 210000004369 blood Anatomy 0.000 title abstract description 16
- 239000008280 blood Substances 0.000 title abstract description 15
- 238000001514 detection method Methods 0.000 title abstract description 13
- 239000003112 inhibitor Substances 0.000 claims abstract description 27
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 25
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 230000001681 protective effect Effects 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 4
- 238000012360 testing method Methods 0.000 claims description 12
- 238000004159 blood analysis Methods 0.000 claims description 9
- 239000011521 glass Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 abstract description 12
- 239000005556 hormone Substances 0.000 abstract description 12
- 102000012479 Serine Proteases Human genes 0.000 abstract description 5
- 108010022999 Serine Proteases Proteins 0.000 abstract description 5
- 230000009849 deactivation Effects 0.000 abstract description 4
- 239000002532 enzyme inhibitor Substances 0.000 abstract description 4
- 229940125532 enzyme inhibitor Drugs 0.000 abstract description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract description 2
- 239000003001 serine protease inhibitor Substances 0.000 abstract description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 2
- 229940122055 Serine protease inhibitor Drugs 0.000 abstract 1
- 101710102218 Serine protease inhibitor Proteins 0.000 abstract 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- 238000004555 blood preservation Methods 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 description 15
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 10
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
Images
Landscapes
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The utility model provides a vacuum blood collection tube for diabetes active peptide blood sample detection, comprising an original tube and a rubber plug. The vacuum blood collection tube is characterized in that the original tube is filled with anti-coagulants and inhibitors; the anti-coagulants contain EDTA salt, heparin salt, citrate, buffer solution, blood preservation liquid and other anticoagulant substances; the inhibitor is enzyme inhibitor, and is especially DPP-IV inhibitor, serine protease inhibitor and others; the anti-coagulants and the inhibitors can be added in a manner of spraying on the tube wall of the original tube, or the liquid of anti-coagulants and the inhibitors can be directly added into the original tube, or powder or particles of the anti-coagulants and the inhibitors can be directly added into the original tube; a protective cap can be disposed outside of the rubber plug, which can be replaced by an aluminum membrane. The vacuum blood collection tube for diabetes active peptide blood sample detection is advantageous in that at the time of blood drawing, the blood directly acts with the inhibitors, which effectively inhibits deactivation effect of DPP-IV and serine protease and others on active peptide and relative hormones; precious time for clinic detection is gained and detection efficiency is improved.
Description
Technical field
This utility model is a kind of vacuum test tube, particularly a kind of diabetic activity peptide blood examination vacuum test tube.
Background technology
Diabetes are the high and diseases very harmful to human body of a kind of sickness rate, and the earlier detection diabetes are very important to people's health.Because of diabetes and glucagon, stomach Pepstatin, that glucagon presses down peptide-1, incretin, stomach growth hormone isoreactivity peptide and associated hormone is closely related.So, now except by the variation of human insulin is monitored the diabetes, can also be by diabetes be monitored in the variation of human body bioactive peptide and associated hormone.Bioactive peptide is the general name of multiple peptide, and bioactive peptide and hormone are active substances important in the human body, and the variation of a lot of bioactive peptide and hormone and generation, development, the treatment of diabetes are closely related.So we can realize the early diagnosis to diabetes by the variation of bioactive peptide in the human body.Because the existence of enzymes such as dipeptidyl peptidase-IV (DPP-IV), serine protease in the human body makes and brings very big difficulty to routine clinical detection related activity peptide and hormone by the bioactive peptide inactivation relevant with diabetes.
Summary of the invention
The purpose of this utility model is in order to overcome the existing defective that bioactive peptide or associated hormone inactivation take place when detecting diabetes by bioactive peptide, invent a kind of enzymes such as dipeptidyl peptidase-IV (DPP-IV), serine protease that can suppress to diabetic activity peptide and the associated hormone blood examination vacuum test tube of bioactive peptide generation deactivation.
The purpose of this utility model realizes as follows: described diabetic activity peptide blood examination vacuum test tube, comprise former pipe and plug, and it is characterized in that: former pipe is built-in with anticoagulant and inhibitor.
The adding mode of described anticoagulant and inhibitor can be that anticoagulant and inhibitor are sprayed on the tube wall of former pipe; Also anticoagulant and inhibitor liquid directly can be added former pipe; Also can be directly anticoagulant and inhibitor powder or granule be added former pipe.
Described plug outside is provided with protective cap.
Described former pipe is with plastics or glass manufacturing.
Good effect of the present utility model is as follows: this utility model combines vacuum blood specimen collection container and inhibitor, during blood drawing, direct and the inhibitor effect of blood, effectively suppressed dipeptidyl peptidase-IV (DPP-IV), the deactivation that enzymes such as serine protease produce bioactive peptide or hormone, for Clinical detection tries to gain time precious to one, for routine clinical test item is laid firm foundations, the relevant bioactive peptide of diabetes is detected become possibility as routine clinical detection, improved the efficient of scientific research and Clinical detection diabetes associated hormone or bioactive peptide, opened up new way for research treatment diabetes and lay the foundation.
Description of drawings
Fig. 1 is this utility model first example structure figure
Fig. 2 is this utility model second example structure figure
Fig. 3 is this utility model the 3rd example structure figure
Among the figure: 1 former pipe 2 plugs, 3 anticoagulant and enzyme inhibitor
4 protective caps
The specific embodiment
Shown in Figure 3 as Fig. 1 Fig. 2, described diabetic activity peptide blood examination vacuum test tube comprises former pipe 1 and plug 2, and it is characterized in that: former pipe 1 is built-in with anticoagulant and inhibitor 3.
The adding mode of described anticoagulant and inhibitor 3 can be that anticoagulant and inhibitor 3 are sprayed at (see figure 1) on the tube wall of former pipe 1; Also anticoagulant and inhibitor 3 liquid directly can be added former pipe 1 (see figure 2); Also can be directly anticoagulant and inhibitor 3 powder or granule be added former pipe 1 (see figure 3).
Described plug 2 outsides are provided with protective cap 4.
Described former pipe 1 is with plastics or glass manufacturing.
This utility model combines vacuum blood specimen collection container and enzyme inhibitor, during blood drawing, direct and the enzyme inhibitor effect of blood, effectively suppressed dipeptidyl peptidase-IV (DPP-IV), the deactivation that enzymes such as serine protease produce bioactive peptide and associated hormone, for Clinical detection tries to gain time precious to one, for routine clinical test item is laid firm foundations, make the routine clinical detection bioactive peptide relevant with diabetes become possibility, improved the efficient of scientific research and Clinical detection diabetes associated hormone or bioactive peptide, opened up new way for research treatment diabetes and lay the foundation.
In concrete enforcement, described anticoagulant can be selected edta salt, heparinate, citrate, buffer, anticoagulant for storage of whole blood and anticoagulant class material for use; Described inhibitor can be selected proteases inhibitors for use; Described proteases inhibitors can be selected dipeptidyl peptidase-IV (DPP-IV), serpin for use.
Claims (4)
1. a diabetic activity peptide blood examination vacuum test tube comprises former pipe and plug, and it is characterized in that: former pipe is built-in with anticoagulant and inhibitor.
2. diabetic activity peptide blood examination vacuum test tube according to claim 1, it is characterized in that: the adding mode of described anticoagulant and inhibitor can be that anticoagulant and inhibitor are sprayed on the tube wall of former pipe; Also anticoagulant and inhibitor liquid directly can be added former pipe; Also can be directly anticoagulant and inhibitor powder or granule be added former pipe.
3. diabetic activity peptide blood examination vacuum test tube according to claim 1 is characterized in that: be provided with protective cap outside the described plug.
4. diabetic activity peptide blood examination vacuum test tube according to claim 1, it is characterized in that: described former pipe is with plastics or glass manufacturing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201220533564 CN203169191U (en) | 2012-10-18 | 2012-10-18 | Vacuum blood collection tube for diabetes active peptide blood sample detection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201220533564 CN203169191U (en) | 2012-10-18 | 2012-10-18 | Vacuum blood collection tube for diabetes active peptide blood sample detection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203169191U true CN203169191U (en) | 2013-09-04 |
Family
ID=49065951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201220533564 Expired - Lifetime CN203169191U (en) | 2012-10-18 | 2012-10-18 | Vacuum blood collection tube for diabetes active peptide blood sample detection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203169191U (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103610475A (en) * | 2013-11-08 | 2014-03-05 | 付士明 | Disposable cerebrospinal fluid collecting container set |
| CN105286885A (en) * | 2015-09-17 | 2016-02-03 | 安徽信灵检验医学科技有限公司 | Blood collection tube applicable to medical clinical examination and manufacturing method of blood collection tube |
| CN106102689A (en) * | 2014-03-18 | 2016-11-09 | 泰尔茂株式会社 | Blood sampling utensil and the manufacture method of blood sampling utensil |
| EP3427833A1 (en) | 2017-07-10 | 2019-01-16 | Victor Lind | A device for test preparation of blood for determination of glucose concentration in blood plasma |
| WO2019144692A1 (en) * | 2018-01-24 | 2019-08-01 | 广州市进德生物科技有限公司 | Glucagon protectant and use thereof |
-
2012
- 2012-10-18 CN CN 201220533564 patent/CN203169191U/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103610475A (en) * | 2013-11-08 | 2014-03-05 | 付士明 | Disposable cerebrospinal fluid collecting container set |
| CN103610475B (en) * | 2013-11-08 | 2015-09-09 | 付士明 | Disposable cerebrospinal fluid collection container suit |
| CN106102689A (en) * | 2014-03-18 | 2016-11-09 | 泰尔茂株式会社 | Blood sampling utensil and the manufacture method of blood sampling utensil |
| CN106102689B (en) * | 2014-03-18 | 2019-08-06 | 泰尔茂株式会社 | Blood sampling utensil and the blood sampling manufacturing method of utensil |
| CN105286885A (en) * | 2015-09-17 | 2016-02-03 | 安徽信灵检验医学科技有限公司 | Blood collection tube applicable to medical clinical examination and manufacturing method of blood collection tube |
| EP3427833A1 (en) | 2017-07-10 | 2019-01-16 | Victor Lind | A device for test preparation of blood for determination of glucose concentration in blood plasma |
| WO2019144692A1 (en) * | 2018-01-24 | 2019-08-01 | 广州市进德生物科技有限公司 | Glucagon protectant and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN203169191U (en) | Vacuum blood collection tube for diabetes active peptide blood sample detection | |
| Bøtker et al. | Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial | |
| Kojima et al. | The white blood cell count is an independent predictor of no‐reflow and mortality following acute myocardial infarction in the coronary interventional era | |
| Kim et al. | Impact of postdischarge statin withdrawal on long-term outcomes in patients with acute myocardial infarction | |
| CN103797350A (en) | Sample collection kit | |
| CN104673623A (en) | Blood sample collecting device | |
| Valerio et al. | Immediate and late impact of reperfusion therapies in acute pulmonary embolism | |
| CN202277339U (en) | Vacuum blood collection tube of hypertension blood sample | |
| WO2003025569A1 (en) | Method of detecting cellular immunity and application thereof to drugs | |
| CN201158654Y (en) | Vitrification refrigeration cell carrier | |
| CN103059623B (en) | PET (polyethylene terephthalate) impermeable membranization agent, impermeable membranization PET blood collection tube, and corresponding preparation methods | |
| CN203720163U (en) | Alpha-L-fucosidase detection kit | |
| Park et al. | Suppressive effects of Benincasae hispida on allergic inflammation | |
| El-Mahdy et al. | Histamine protects against the acute phase of experimentally-induced hepatic ischemia/re-perfusion | |
| CN205146299U (en) | Follow -on blood sampling test -tube rack | |
| Ederhy et al. | Preventing cerebrovascular accidents during atrial fibrillation | |
| CN201008684Y (en) | Portable insulin syringe | |
| CN204523041U (en) | A kind of endocrine storing unit | |
| CN203802472U (en) | Dynamic monitor for blood glucose | |
| CN204528115U (en) | Anaerobism sample stores conveyer | |
| CN108309645A (en) | A kind of division of endocrinology diabetes patient nursing for treating box | |
| CN205761240U (en) | Adopt inspection sleeve pipe and gag thereof | |
| CN202853945U (en) | Safe collection and delivery box for urine organism | |
| CN202942533U (en) | Disposable plastic tubular disinfectant cotton swab | |
| CN209611334U (en) | A kind of Novel treating tray |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20130904 |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Fu Shiming Document name: Notice of Expiration and Termination of Patent Right |